PharmaCyte Biotech, Inc. Quarterly Common Stock, Shares, Outstanding from Q1 2012 to Q2 2024

Taxonomy & unit
us-gaap: shares
Description
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Summary
PharmaCyte Biotech, Inc. quarterly Common Stock, Shares, Outstanding history and growth rate from Q1 2012 to Q2 2024.
  • PharmaCyte Biotech, Inc. Common Stock, Shares, Outstanding for the quarter ending July 31, 2024 was 7.72M shares, a 12.1% decline year-over-year.
Common Stock, Shares, Outstanding, Quarterly (shares)
Common Stock, Shares, Outstanding, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 7.72M -1.06M -12.1% Jul 31, 2024 10-Q 2024-09-17
Q1 2024 8.04M -8.76M -52.1% Apr 30, 2024 10-Q 2024-09-17
Q4 2023 8.52M -9.69M -53.2% Jan 31, 2024 10-Q 2024-03-18
Q3 2023 8.7M -10.8M -55.4% Oct 31, 2023 10-Q 2023-12-15
Q2 2023 8.78M -12M -57.7% Jul 31, 2023 10-Q 2023-09-18
Q1 2023 16.8M -3.93M -19% Apr 30, 2023 10-K 2024-08-13
Q4 2022 18.2M -2.51M -12.1% Jan 31, 2023 10-Q 2023-03-16
Q3 2022 19.5M -1.19M -5.74% Oct 31, 2022 10-Q 2022-12-14
Q2 2022 20.8M +19.1M +1187% Jul 31, 2022 10-Q 2022-09-14
Q1 2022 20.7M +19.1M +1203% Apr 30, 2022 10-K 2023-07-31
Q4 2021 20.7M -2.32B -99.1% Jan 31, 2022 10-Q 2022-03-15
Q3 2021 20.7M -2.31B -99.1% Oct 31, 2021 10-Q 2021-12-14
Q2 2021 1.61M -1.87B -99.9% Jul 31, 2021 10-Q 2021-09-14
Q1 2021 1.59M +498K Apr 30, 2021 10-K 2022-07-28
Q4 2020 2.34B +913M +63.9% Jan 31, 2021 10-Q 2021-03-12
Q3 2020 2.33B +1B +75.3% Oct 31, 2020 10-Q 2020-12-11
Q2 2020 1.88B +617M +49% Jul 31, 2020 10-Q 2020-09-11
Q1 2020 1.09M* -1.18B Apr 30, 2020 10-K 2021-08-10
Q4 2019 1.43B +302M +26.8% Jan 31, 2020 10-Q 2020-03-13
Q3 2019 1.33B +250M +23.2% Oct 31, 2019 10-Q 2019-12-23
Q2 2019 1.26B +179M +16.6% Jul 31, 2019 10-Q 2019-09-13
Q1 2019 1.19B +173M +17% Apr 30, 2019 10-K 2020-08-13
Q4 2018 1.13B +147M +15% Jan 31, 2019 10-Q 2019-03-14
Q3 2018 1.08B +108M +11.1% Oct 31, 2018 10-Q 2018-12-14
Q2 2018 1.08B +106M +10.9% Jul 31, 2018 10-Q 2018-09-12
Q1 2018 1.01B +108M +11.9% Apr 30, 2018 10-K 2019-08-13
Q4 2017 980M +108M +12.4% Jan 31, 2018 10-Q 2018-03-19
Q3 2017 973M +124M +14.6% Oct 31, 2017 10-Q 2017-12-14
Q2 2017 973M +125M +14.7% Jul 31, 2017 10-Q 2017-09-13
Q1 2017 905M +124M +15.9% Apr 30, 2017 10-K 2018-07-20
Q4 2016 872M +101M +13.1% Jan 31, 2017 10-Q/A 2017-03-13
Q3 2016 849M +102M +13.6% Oct 31, 2016 10-Q 2016-12-02
Q2 2016 849M +106M +14.3% Jul 31, 2016 10-Q 2016-09-06
Q1 2016 781M +48.5M +6.62% Apr 30, 2016 10-K 2017-07-27
Q4 2015 771M +67.9M +9.65% Jan 31, 2016 10-Q 2016-03-08
Q3 2015 747M +51.3M +7.37% Oct 31, 2015 10-Q/A 2016-01-19
Q2 2015 743M +32.3M +4.54% Jul 31, 2015 10-Q/A 2016-01-19
Q1 2015 733M +42.1M +6.1% Apr 30, 2015 10-K 2016-07-29
Q4 2014 703M +100M +16.7% Jan 31, 2015 10-Q 2015-03-13
Q3 2014 696M +108M +18.3% Oct 31, 2014 10-Q 2014-12-15
Q2 2014 710M +173M +32.3% Jul 31, 2014 10-Q 2014-09-15
Q1 2014 691M +209M +43.3% Apr 30, 2014 10-K/A 2016-01-19
Q4 2013 603M +145M +31.7% Jan 31, 2014 10-Q 2014-03-17
Q3 2013 588M +144M +32.4% Oct 31, 2013 10-Q 2013-12-16
Q2 2013 537M Jul 31, 2013 10-Q 2013-09-16
Q1 2013 482M +65.8M +15.8% Apr 30, 2013 10-K 2014-08-04
Q4 2012 458M Jan 31, 2013 10-Q 2013-03-26
Q3 2012 445M Oct 31, 2012 10-Q 2012-12-26
Q1 2012 416M Apr 30, 2012 10-K 2013-07-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.